Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-16

Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CEP-33457 for efficacy and safety in systemic lupus erythematosus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CEP-33457

Snippet

Sponsor: Cephalon, Inc. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2022-12-16